Partnering with YS Biopharma
YS Biopharma is committed to maximizing the impact of its technology platform in immuno-oncology and infectious disease. Given the broad potential of our platform and the broad capabilities of the Company, we are interested in working with partners with complementary programs and assets that could help accelerate development of best-in-class therapeutics.
If you’d like to learn more about partnering with YS Biopharma, please contact our business development group at email@example.com.
To expand beyond our in-house development capabilities, we have established collaborative relationships with leading research groups, government entities, academic institutions and commercial partners.
Our collaborations have focused on protein biology, RNA chemistry and biology, immunology, oncology and biomanufacturing in order to develop a new class of biologics for prevention and therapy of cancer, infectious disease and other disorders. We have engaged in research and development collaborations with the Scripps Research Institute, the U.S. Centers for Disease Control and Prevention, the National Institutes of Health, the U.S. Army Medical Research Institute for Infectious Diseases, the Duke-NUS Medical School, the DSO National Laboratories of Singapore, the QIMR Berghofer Medical Research Institute in Australia, the China Centers for Disease Control and Prevention, the Chinese Academy of Sciences, Sun Yat-Sen University of China.